Department of Parasitology, Faculty of Medicine, Universiti Malaya, 50603, Kuala Lumpur, Malaysia.
Trop Biomed. 2024 Jun 1;41(2):190-195. doi: 10.47665/tb.41.2.009.
The Plasmodium secreted protein with an altered thrombospondin repeat (SPATR) has been known to play an important role in the malaria parasite's invasion into host erythrocytes. This protein is immunogenic and has been considered as one of the potential vaccine candidates against malaria parasite infection. Thus far, only a handful immunological studies have been carried out on P. knowlesi SPATR (PkSPATR), and none of these studies investigated the immunoprotective properties of the protein. In the present study, the ability of anti-PkSPATR antibodies to inhibit invasion of human erythrocytes was assessed in an in vitro merozoite invasion inhibition assay. The antibodies were harvested from the serum of a rabbit which was immunised with recombinat PkSPATR. Results from the merozoite invasion inhibition assay revealed significant antibody invasion inhibitory activity in a concentration dependent manner (concentration range: 0.375 - 3.00 mg/ml) with inhibition rate ranging from 20% to 32%. Future studies, such as anti-PkSPATR antibodies inhibitory effect on sporozoite invasion of human liver cells, need to be carried out to assess the potential of PkSPATR as a knowlesi malaria vaccine candidate.
疟原虫分泌的富含血栓反应蛋白重复序列(SPATR)的蛋白,在疟原虫入侵宿主红细胞的过程中发挥着重要作用。该蛋白具有免疫原性,被认为是疟疾寄生虫感染潜在的疫苗候选物之一。迄今为止,仅有少数关于伯氏疟原虫 SPATR(PkSPATR)的免疫学研究,而且这些研究都没有调查该蛋白的免疫保护特性。在本研究中,通过体外配子体入侵抑制试验评估了抗 PkSPATR 抗体抑制人红细胞入侵的能力。从用重组 PkSPATR 免疫的兔子血清中采集抗体。配子体入侵抑制试验的结果表明,抗体具有浓度依赖性的入侵抑制活性(浓度范围:0.375-3.00mg/ml),抑制率为 20%-32%。需要开展进一步的研究,如抗 PkSPATR 抗体对人肝细胞中孢子体入侵的抑制作用,以评估 PkSPATR 作为间日疟疫苗候选物的潜力。